IA
RPRX icon

IFG Advisory’s Royalty Pharma RPRX Stock Holding History

IFG Advisory’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Buy
+37
New +$1.93K ﹤0.01% 2109

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFG Advisory's RPRX Position: Q2 2026 in Review

IFG Advisory opened a new position in Royalty Pharma (RPRX) in Q2 2026: 37 shares worth $2.08K. The stake represents ﹤0.01% of the portfolio and ranks #2109 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • IFG Advisory held 37 shares of Royalty Pharma worth $2.08K as of Q2 2026.
  • Royalty Pharma was a new IFG Advisory position in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #2109 holding.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.